These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 31582207)
1. Response to the Letter to the Editor From Dr Kawada, "Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors for the Treatment of Hypertensive Patients With Type 2 Diabetes Mellitus". Mavrakanas TA; Lipman ML Can J Diabetes; 2020 Feb; 44(1):5. PubMed ID: 31582207 [No Abstract] [Full Text] [Related]
2. Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors for the Treatment of Hypertensive Patients With Type 2 Diabetes Mellitus. Kawada T Can J Diabetes; 2020 Feb; 44(1):4. PubMed ID: 30833122 [No Abstract] [Full Text] [Related]
3. Angiotensin-Converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers for the Treatment of Hypertension in Adults With Type 2 Diabetes: Why We Favour Angiotensin Receptor Blockers. Mavrakanas TA; Lipman ML Can J Diabetes; 2018 Apr; 42(2):118-123. PubMed ID: 29602404 [TBL] [Abstract][Full Text] [Related]
4. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension. Kuan YC; Huang KW; Yen DJ; Hu CJ; Lin CL; Kao CH Int J Cardiol; 2016 Oct; 220():462-6. PubMed ID: 27390970 [TBL] [Abstract][Full Text] [Related]
5. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154 [TBL] [Abstract][Full Text] [Related]
6. Are angiotensin-converting enzyme inhibitors the best treatment for hypertension in type 2 diabetes? Komers R; Anderson S Curr Opin Nephrol Hypertens; 2000 Mar; 9(2):173-9. PubMed ID: 10757223 [TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: a nationwide study. Shih CJ; Chu H; Ou SM; Chen YT Int J Cardiol; 2015 Nov; 199():283-9. PubMed ID: 26218587 [TBL] [Abstract][Full Text] [Related]
8. Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers--a gap in evidence-based medicine. Ball SG; White WB Am J Cardiol; 2003 May; 91(10A):15G-21G. PubMed ID: 12781904 [TBL] [Abstract][Full Text] [Related]
9. First-line renin-angiotensin system inhibitors vs. other first-line antihypertensive drug classes in hypertensive patients with type 2 diabetes mellitus. Wang G; Chen Y; Li L; Tang W; Wright JM J Hum Hypertens; 2018 Jul; 32(7):494-506. PubMed ID: 29713053 [TBL] [Abstract][Full Text] [Related]
10. Renoprotection by angiotensin-receptor blockers and ACE inhibitors in hypertension. Opie LH Lancet; 2001 Dec; 358(9296):1829-31. PubMed ID: 11741617 [No Abstract] [Full Text] [Related]
11. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Vijan S; Hayward RA Ann Intern Med; 2003 Apr; 138(7):593-602. PubMed ID: 12667032 [TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme inhibition or angiotensin receptor blockade in hypertensive diabetics? Laverman G; Ruggenenti P; Remuzzi G Curr Hypertens Rep; 2003 Oct; 5(5):364-7. PubMed ID: 12948427 [TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of the effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers on insulin sensitivity in hypertensive patients without diabetes. Yang Y; Wei RB; Wang ZC; Wang N; Gao YW; Li MX; Qiu Q Diabetes Res Clin Pract; 2015 Mar; 107(3):415-23. PubMed ID: 25649909 [TBL] [Abstract][Full Text] [Related]
14. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension. Weber MA J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125 [TBL] [Abstract][Full Text] [Related]
15. The role of the renin angiotensin hormonal system in the metabolic syndrome and type 2 diabetes. Nosadini R; Tonolo G Nutr Metab Cardiovasc Dis; 2004 Apr; 14(2):88-93. PubMed ID: 15242241 [TBL] [Abstract][Full Text] [Related]
16. Managing hypertension using combination therapy. Frank J Am Fam Physician; 2008 May; 77(9):1279-86. PubMed ID: 18540493 [TBL] [Abstract][Full Text] [Related]
17. Incidence of new stroke or new myocardial infarction or death at 39-month follow up in patients with diabetes mellitus, hypertension, or both treated with and without angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Ravipati G; Aronow WS; Ahn C; Alappat RM; McClung JA; Weiss MB Am J Ther; 2009; 16(1):2-4. PubMed ID: 19114876 [TBL] [Abstract][Full Text] [Related]
18. Reply to Letter to the Editor-Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction. Lee DH J Cardiovasc Pharmacol Ther; 2019 Jul; 24(4):398. PubMed ID: 31043058 [No Abstract] [Full Text] [Related]
19. A review of chemical therapies for treating diabetic hypertension. Sarafidis PA; Alexandrou ME; Ruilope LM Expert Opin Pharmacother; 2017 Jun; 18(9):909-923. PubMed ID: 28480805 [TBL] [Abstract][Full Text] [Related]
20. Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: Systematic review and meta-analysis. Salvador GL; Marmentini VM; Cosmo WR; Junior EL Eur J Prev Cardiol; 2017 Dec; 24(18):1914-1924. PubMed ID: 28862020 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]